Press Release

14th July, 2026 Corporate Relationship Department The Manager - Listing BSE Limited National Stock Exchange of India Ltd. Mumbai 400001 Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Press Release under Regulation 30 of the SEBI (LODR) Regulations, 2015 Ref:- Earlier intimations dated 8th July, 2026 With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the completion of acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited. This is for your information and records. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: As above Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd NATCO House Road No.2, Banjara Hills Hyderabad-500 034, India NATCO Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited Hyderabad, India – Tuesday, July 14, 2026 – NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) (“NATCO”) announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (“Adcock Ingram”), a leading South African pharmaceutical and healthcare company. With the completion of this transaction, NATCO’s shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary Limited, NATCO’s wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around ₹ 1,060 crores at the transaction exchange rate. Strategic milestone in NATCO’s African growth journey The completion of the additional stake acquisition marks another significant milestone in NATCO’s long-term Africa strategy. NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram’s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025. Pursuant to that, NATCO’s Board further approved the acquisition of an additional 13.25% stake in July 2026, and the transaction has now been completed following the satisfaction of customary closing conditions and regulatory requirements. About NATCO Pharma Limited NATCO Pharma Limited is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of ~US$ 1.82 billion. Established in 1981, NATCO Pharma is well recognised for its innovation in pharmaceutical R&D and emphasis on developing niche, high potential molecules. The company has a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories. Products are manufactured across 9 state-of-the-art facilities certified and approved by leading global regulatory authorities, including the US FDA, Brazil’s ANVISA, Health Canada, and the World Health Organisation. NATCO Pharma exports its products to more than 50 countries worldwide including USA, Brazil and Canada. Natco Pharma Limited Regd. Off. NATCO Pharma Ltd NATCO House Road No.2, Banjara Hills Hyderabad-500 034, India About Adcock Ingram Holdings Proprietary Limited Adcock Ingram is a South African pharmaceutical company established in 1891 and ranked 2nd in the private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both the private and public sectors of the market. Its portfolio includes an extensive range of Prescription, Over-the-counter (OTC), Consumer and Hospital products, manufactured in three facilities in South Africa and two in India. Its extensive portfolio of products includes well-known household brands such as Panado, Allergex, Epi-max, Citro-Soda, and Myprodol. Adcock Ingram has a 10% market share of the private market, is the leader in the OTC pharmaceutical market, and is the largest supplier of hospital and critical care products in South Africa. For further information please contact: Rajeev Menon – Manager, Investor Relations Email: r.menon@natcopharma.co.in Tel: 040-23547532 / Ext – 323 Follow us on: X (formerly Twitter): https://twitter.com/pharma_natco LinkedIn: https://www.linkedin.com/company/ natcopharma